Answers are grounded in this paper and cite their sources.
Shows SIRT3 improves outcomes related to aging and inflammation in mice, suggesting new therapeutic strategies.
Trained immunity is a state of heightened immune response that is initiated in hematopoietic stem cells (HSCs) and mediated mainly by their myeloid progeny. Aging-associated inflammation drives many aging-related diseases, yet its biological origin is largely unknown. Here we show that SIRT3, a mitochondrial deacetylase highly expressed in HSCs but reduced during aging, suppresses the HSC response to aging that drives maladaptive trained immunity, chronic inflammation and tissue functional decline in mice. Overexpression of SIRT3 in HSCs not only ameliorates aging-associated HSC decline, but also improves the function of distant tissues, including attenuation of age-related declines in cognition and motility, via myeloid cells with modulated inflammatory programs. These findings reveal that HSC aging is a driver of aging-associated inflammation through maladaptive trained immunity and broaden the possible clinical applications of targeting HSCs from hematological diseases to include countering aging-associated physiological decline and improving healthspan. Mu, Barthez, Feng, Chen, Wang and colleagues report that SIRT3 suppresses the hematopoietic stem cell response to aging that drives maladaptive trained immunity, chronic inflammation and tissue functional decline in mice via inflammatory myeloid cells.
No takes yet. Share an insight, caveat, or question.
Mu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: